First-Line Selpercatinib in RET Fusion-Positive NSCLC

Progression-free survival was longer with selpercatinib than with platinum-based chemotherapy plus pemetrexed with or without pembrolizumab.

RET fusions occur in 1% to 2% of non–small-cell lung cancers (NSCLCs), usually in young light or never smokers with adenocarcinoma histology, and are associated with a high incidence of central nervous system (CNS) metastases. Selpercatinib is a highly potent RET inhibitor that has demonstrated significant efficacy in phase 1 and 2 trials of RET fusion-positive NSCLC.

Now, researchers report an interim analysis of an industry-sponsored, open-label, phase 3 trial in which 261 patients with RET fusion-positive NSCLC were randomized to receive selpercatinib (160 mg twice daily; n=159) or investigator's choice of platinum-based chemotherapy plus pemetrexed with or without pembrolizumab (n=102).

The intention-to-treat (ITT) pembrolizumab populatio…

Reviewing Author

Jyoti D. Patel, MD, FASCO

Disclosures

Consultant/Advisory BoardTakeda; AstraZeneca; AnHeart; Lilly; AbbVie; Blueprint; Gilead; Sanofi; Daiichi Sankyo; Genentech

Jyoti D. Patel, MD, FASCO

Disclosures

Consultant/Advisory BoardTakeda; AstraZeneca; AnHeart; Lilly; AbbVie; Blueprint; Gilead; Sanofi; Daiichi Sankyo; Genentech

First-Line Selpercatinib in RET Fusion-Positive NSCLC

Topics

Reviewing Author